Related Experiment Video

Updated: Aug 13, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Antithrombotic therapy for congestive heart failure

I Chung1, G Y H Lip

  • 1Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK.

International Journal of Clinical Practice
|January 18, 2006
PubMed

Insights

Congestive heart failure patients face higher risks of blood clots. This review examines stroke risks and antithrombotic therapy effectiveness and safety in heart failure patients.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacology

Background:

  • Patients with congestive heart failure (CHF) exhibit an elevated risk of thromboembolic events.
  • Significant uncertainty exists regarding the optimal antithrombotic therapy for this patient population.
  • Limited evidence currently supports oral anticoagulation, with major trial data anticipated.

Purpose of the Study:

  • To review the current evidence on stroke and thromboembolic event risks in patients with CHF.
  • To evaluate the efficacy and safety of antithrombotic therapies in this cohort.
  • To address the ongoing debate surrounding antithrombotic treatment in heart failure.

Main Methods:

  • Systematic literature review of existing studies.
  • Analysis of randomized controlled trials and observational data.
  • Synthesis of evidence on antithrombotic drug risks and benefits.

Main Results:

  • Congestive heart failure patients have a demonstrably higher incidence of thromboembolic events.
  • Aspirin may pose risks in heart failure, potentially interacting with ACE inhibitors and increasing hospitalizations.
  • Evidence for oral anticoagulation is currently limited but expanding with new trial data.

Conclusions:

  • Further research and large-scale trials are crucial to guide antithrombotic therapy decisions in CHF.
  • The potential risks of aspirin in CHF warrant careful consideration.
  • A nuanced approach is needed to balance thromboembolic risk reduction with potential adverse effects of treatment.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...